Abstract：The emergency of global pandemic Covid-19 is a great challenge for the innovation capability in biomedical field.Many countries,companies and institutions all over the world have joined in the “competition”of vaccine research and development.However,it is not objective to simply characterize this vaccines development as competitive or cooperative.This paper claimed that both the uncertainty of virus and the complexity of R&D process determine the extremely high risks of R&D investment.Driven by different motives of R&D investment,micro-actors will show different characteristics.In this paper,214 research and development institutions participating in 166 candidate vaccine projects officially announced by WHO are taken as samples.This paper describs the prospect of vaccine research and development “competition”based on innovation theory,objectively analyzes the characteristics of participants in research and development,innovation motivation and the relationship with research and development mode,helps to understand the research and development investment motivation and innovation mode of micro subjects,and provides policy-making references for the government and public departments to further support the innovation and development of biomedical industry.
王秀芹. 谁在参与新冠疫苗研发“竞赛”——从参与主体特征到研发模式[J]. 中国科技论坛, 2021(2): 1-8.
Wang Xiuqin. Who Are Competing For the Covid-19 Vaccines:Characteristics of Leading-Participants and R&D Mode. , 2021(2): 1-8.
[1]Draft landscape of COVID-19 candidate vaccines[EB/OL]. (2020-07-21)[2020-07-26].https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/. [2]斯托克斯.基础科学与技术创新:巴斯德象限[M].周春彦,谷春立,译.北京:科学出版社,1999. [3]高锦萍,李林,万岩.我国企业研发组织模式创新研究:分类、现状与趋势[J].上海管理科学,2014,36 (1):55-59. [4]CHESBROUGH H W.Open innovation:the new imperative for creating and profiting from technology[M].Boston:Harvard Business School Press,2003. [5]BIANCHI M,CAVALIERE A,CHIARONI D,et al.Organisational modes for open innovation in the bio-pharmaceutical industry:an exploratory analysis[J].Technovation,2011,31 (1):22-33. [6]王勇.开放创新范式下医药研发组织模式研究[J].中国科技论坛,2014 (8):11-15. [7]张立国.新药研发组织模式演化及对我国的启示[D].北京:中国人民解放军军事医学科学院,2013. [8]Vaccine Types[EB/OL]. (2020-03-01)[2020-05-01]. https://www.vaccines.gov/basics/types. [9]新京报.新冠肺炎下的 “疫苗赛跑”[EB/OL]. (2020-03-12)[2020-03-20].https://baijiahao.baidu.com/s?id=1660390439012225881&wfr=spider&for=pc. [10]研发新冠疫苗 全球96个团队谁能跑赢[EB/OL]. (2020-03-20)[2020-04-11].https://finance.sina.com.cn/wm/2020-03-20/doc-iimxyqwa1933713.shtml. [11]STEPHAN P. How economics shapes science[M].London:Harvard University,2012. [12]中国疫苗行业协会各会员单位积极投身新冠肺炎疫情防控[EB/OL]. (2020-02-11)[2020-05-12].http://www.cujin.org/NewsDetail-72.aspx. [13]熊彼特.资本主义、社会主义与民主主义[M].北京:商务印书馆,1979. [14]ROIJAKKERS N,HAGEDOORN J.Inter-firm R&D partnering in pharmaceutical biotechnology since 1975:trends,patterns,and networks[J].Research policy,2006,35 (3):431-446. [15]LEE C W.Strategic alliances influence on small and medium firm performance[J].Journal of business research,2007,60 (7):731-741. [16]SEBASTIAN K,JUTTA S,ISABELL M.More is not always better:effects of collaboration breadth and depth on radical and incremental innovation performance at the project level[J].Research policy,2019,48 (1):1-10. [17]MARIANNE S,EINAR R.The interplay of cognitive and relational social capital dimensions in university-industry collaboration:overcoming the experience barrier[J].Research policy,2018,47 (10):1964-1974. [18]KIM K Y.Strategic R&D alliance factors that impact innovation success in the biotechnology industry[J].International journal of technology management,2012,59 (1/2):116-138. [19]薛澜.中国科技创新政策40年的回顾与反思[J].科学学研究,2018,36 (12):3-5+11. [20]弗里曼.工业创新经济学:第三版[M].华宏勋,华宏慈,译.北京:北京大学出版社,2004. [21]SAKAKIBARA M.Heterogeneity of firm capabilities and cooperative research and development:an empirical examination of motives[J].Strategic management journal,1998,18 (S1):143-164. [22]中国工程科技发展战略研究院.2015中国战略性新兴产业发展报告[R].北京:科学出版社,2014.
2021, 
